GENOCEA BIOSCIENCES, INC.

(GNCA)
  Report
Delayed Nasdaq  -  05/20 04:00:00 pm EDT
0.2089 USD   -4.92%
05/05GENOCEA BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
05/05Genocea Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/29Top Premarket Decliners
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Genocea Biosciences Teams Up with Janssen to Explore Immunogenicity of Neoantigens

01/04/2022 | 03:03pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
GENOCEA BIOSCIENCES, INC. -4.92% 0.2089 Delayed Quote.-81.99%
JOHNSON & JOHNSON 1.75% 176.98 Delayed Quote.1.68%
All news about GENOCEA BIOSCIENCES, INC.
05/05GENOCEA BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
05/05Genocea Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31..
CI
04/29Top Premarket Decliners
MT
04/29HC Wainwright Downgrades Genocea Biosciences to Neutral From Buy
MT
04/29Stifel Downgrades Genocea Biosciences to Hold From Buy, Adjusts Price Target to $0.16 F..
MT
04/28GENOCEA BIOSCIENCES : Initiates Restructuring and Announces Plan to Explore Strategic Alte..
PU
04/28Genocea Announces Plan to Explore Strategic Alternatives
CI
04/28GENOCEA BIOSCIENCES, INC. : Costs Associated with Exit or Disposal Activities, Regulation ..
AQ
04/28Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives
AQ
04/11TRANSCRIPT : Genocea Biosciences, Inc. Presents at AACR Annual Meeting 2022, Apr-08-2022 t..
CI
More news
Analyst Recommendations on GENOCEA BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 0,57 M - -
Net income 2022 -40,5 M - -
Net cash 2022 12,0 M - -
P/E ratio 2022 -0,36x
Yield 2022 -
Capitalization 12,3 M 12,3 M -
EV / Sales 2022 0,49x
Capi. / Sales 2023 -
Nbr of Employees 74
Free-Float 93,7%
Chart GENOCEA BIOSCIENCES, INC.
Duration : Period :
Genocea Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENOCEA BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Last Close Price 0,21 $
Average target price 3,08 $
Spread / Average Target 1 374%
EPS Revisions
Managers and Directors
William D. Clark President, Chief Executive Officer & Director
Diantha Duvall Chief Financial Officer
Kenneth M. Bate Chairman
Jessica Baker Flechtner Chief Scientific Officer
Thomas Andrew Davis Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
GENOCEA BIOSCIENCES, INC.-81.99%12
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567